% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • byecell byecell Mar 17, 2013 10:28 AM Flag

    pancreatic cancers

    Reading about injectable insulin causing cancer.. any insight into whether or not mnkds insulin will or will not have similar issues. If not this should be very positive for them

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • byecell,

      It is not injectable insulin that has been implicated. It is oral and injectable drugs that stimulate the pancreas to release more insulin. Afrezza is essentialy just insulin - it does not further stimulate the pancreas. In fact, Afrezza may allow the pancreas to rest and preserve some function longer. The Technosphere carrier is inert. So Afrezza should not have the problems these other drugs might have.

      "The Food and Drug Administration has announced that it will investigate whether a new class of Type 2 diabetes drugs sometimes called the "gliptins" may increase patients' risk of developing precancerous changes in the pancreas, as well as of developing acute pancreatitis.

      The drugs now under closer FDA scrutiny are called incretin mimetics and include such widely prescribed medications as the drug exenitide (marketed as Byetta and Bydureon), liraglutide (Victoza), sitagliptin (Januvia and Janumet or Juvisync), saxagliptin (Onglyza), alogliptin (Nesina, Kazano and Oseni) and linogliptin (Tradjenta and Jentadueto). All of the drugs in this class help Type 2 diabetes patients control their blood sugar by mimicking the hormones that promote the release of insulin after a meal."

    • You right when you say Afrezza is insulin,your mistaken when you say the other drugs in question are insulin.Apples and oranges...

      "The drugs under review come from a wave of recently approved diabetes medications, including Merck's Januvia and Janumet, Novo Nordisk's Victoza and Bristol-Myers Squibb's Byetta and Bydureon, among others. All the drugs mimic natural hormones that the body usually produces to spur insulin production after a meal. "

      From the article:FDA probes new pancreas risks with diabetes drugs

0.5943-0.0154(-2.53%)Oct 21 4:00 PMEDT